RT Journal Article
T1 Antiplatelet therapy at discharge and long-term prognosis in Takotsubo syndrome: Insights from the Spanish National Registry (RETAKO).
A1 Pereyra, Eduardo
A1 Fernández-Rodríguez, Diego
A1 González-Sucarrats, Silvia
A1 Almendro-Delia, Manuel
A1 Martín, Agustín
A1 de Miguel, Irene Martin
A1 Andrés, Mireia
A1 Duran-Cambra, Alberto
A1 Sánchez-Grande-Flecha, Alejandro
A1 Worner-Diz, Fernando
A1 Núñez-Gil, Iván J
A1 RETAKO investigators, 
K1 Agregação de plaquetas
K1 Antiplatelet treatment
K1 Catecholamines
K1 Catecolaminas
K1 Disfunção endotelial
K1 Endothelial dysfunction
K1 Platelet aggregation
K1 Síndrome de Takotsubo
K1 Takotsubo syndrome
K1 Tratamento antiplaquetário
AB Endothelial dysfunction and platelet activation have been highlighted as possible mediators in Takotsubo syndrome (TTS). Nevertheless, to date, evidence on the usefulness of antiplatelet therapy in TTS remains controversial. The aim of our study is to evaluate long-term prognosis in TTS patients treated with antiplatelet therapy (APT) at hospitalization discharge. An ambispective cohort study from the Spanish National Takotsubo Registry database was performed (June 2002 to March 2017). Patients were divided into two groups: those who received APT at hospital discharge (APT cohort) and those who did not (non-APT cohort). Primary endpoint was all-cause death. Secondary endpoints included the composite of recurrence or readmission and a composite of death, recurrence or readmission. From a total of 741 patients, 728 patients were alive at discharge. Follow-up was performed in 544 patients, who were included in the final analysis: 321 patients (59.0%) in the APT cohort and 223 patients (41.0%) in the non-APT cohort. The APT cohort had a better clinical presentation and received more heart failure and acute coronary syndrome-like therapies (angiotensin converting enzyme inhibitors/angiotensin receptor blockers: 75.1% vs. 51.1%; p Patients with TTS receiving APT at discharge presented better prognosis up to two-years of follow-up compared with their counterparts not receiving APT.
YR 2022
FD 2022-10-11
LK http://hdl.handle.net/10668/22498
UL http://hdl.handle.net/10668/22498
LA en
LA pt
DS RISalud
RD Apr 19, 2025